EXHIBIT 99

                                  RISK FACTORS

         You should carefully consider the risks described below. The risks
described below are not the only ones we face. Additional risks not presently
known to us or that we currently believe are immaterial may also impair our
business operations. Our business, financial condition or results of operation
could be materially adversely affected by any of these risks. The trading price
of our common stock could decline because of any one of these risks.


Our revenues are dependent on the continued research needs of companies in the
pharmaceutical and biotechnology industries.

         We are highly dependent on research and development expenditures by the
pharmaceutical and biotechnology industries. Accordingly, our operations could
be materially and adversely affected by general economic downturns in these
industries and other factors resulting in a decrease in research and development
expenditures. Furthermore, we have benefited from the increasing trend among
pharmaceutical and biotechnology companies to hire outside organizations such as
ours to conduct both small and large research projects. This "outsourcing"
practice has grown substantially over the past several years and we believe that
because of our multiple biologically based capabilities, we are well positioned
to continue to take advantage of this trend. If this trend in outsourcing were
to change and companies in these industries reduced their tendency to outsource
their projects, our operations and financial condition could be materially and
adversely affected.


Competition in the pharmaceutical and biotechnology industry is intense.

         The contract research industry is highly fragmented, with national and
regional companies ranging from large, full-service companies engaging in
contract research and development or reagent services to small, limited-service
companies who specialize in one particular aspect of research and development or
media production. Contract research companies compete on the basis of several
factors, including:

(1)      reputation for on-time quality performance;
(2)      expertise and experience in specific therapeutic areas;
(3)      scope of service offerings and how well such services are integrated;
(4)      strengths in various geographic markets;
(5)      price;
(6)      technological expertise and efficient drug development processes;
(7)      the ability to acquire, process, analyze and report data in a
         timesaving and accurate manner; and
(8)      expertise and experience in health economics.

         Many of our competitors have achieved significant national, regional
and local brand name and product recognition as well as engage in frequent and
extensive advertising and promotional programs. Many of our competitors have
substantially greater financial, technical, marketing, personnel and other
resources than we do. Furthermore, our industry has recently begun to attract
attention from the investment community. This could lead to increased
competition through the availability of additional financial resources for
contract research companies. While we believe that we can compete effectively,
and have done so in the past, we cannot assure you that we will be able to do so
in the future.

<page>

A substantial portion of our revenues have been derived from a limited number of
customers.

         We have one (1) customer who accounted for approximately 35% of our
total annual revenue for the years ended December 31, 2001, 2000 and 1999. The
decrease or loss of business from this customer or any other significant
customer could have a material adverse effect on our results of operations or
financial condition of the company.

         This customer also accounted for 51% of the total revenue of the
Molecular Cell Science division of Cell & Molecular Technologies, Inc. ("CMT"),
one of our subsidiaries, for the year ended December 31, 2001. Another customer
accounted for 20% of the total revenues of Specialty Media, the other division
of CMT, for the year ended December 31, 2001. We do not have long-term contracts
with either of these customers. We believe that these customers will continue to
account for a significant portion of our revenues in the 2002 and 2003 fiscal
years. We cannot assure you, however, that these customers will continue to
generate significant revenues and the decrease or loss of business from either
of these customers, or any other significant customers could have a material
adverse effect on the financial condition of at such division.

Our services are generally provided on a fee-for-services and therefore we bear
the risk that our costs exceed what we charge our customers.

         Most of our contracts for the provision of our services are on a
fee-for-service basis, providing for payments only after certain research
milestones have been reached. We do not receive residual or royalty payments for
future discoveries or uses involving the materials or services provided by us to
our customers. For the years ended December 31, 2001 and 2000, these
fee-for-service contracts accounted for 64% of our total annual revenues,
respectively. Since our contracts are predominantly fee-for-service, we bear the
risk if it costs us more to perform our services than what we charge our
customers. Most of our contracts, including those with governmental agencies,
are terminable by the client immediately or upon notice for a variety of
reasons. Although the contracts often require payment to us for our expenses to
wind down the study and fees earned to date and, in some cases, a termination
fee, the loss of one or more of our large contracts could have a material
adverse effect on our business and operations.


If we are unable to successfully develop and market potential new services, our
growth could be adversely affected.

         A key element of our growth strategy is the successful development and
marketing of new services, which complement or expand our existing business. If
we are unable to develop new services and attract a customer base for those
newly developed services, we will not be able to implement this element of our
growth strategy, and our future business, results of operations and financial
condition could be adversely affected.


A substantial portion of our working capital will be used to fund Sentigen
Corp.'s research efforts which may or may not result in the development of
commercially viable products.

         A substantial portion of our working capital will be used to fund
research and development efforts of Sentigen Corp., our wholly-owned subsidiary.
Sentigen Corp. is in a development stage, having been incorporated in February
2000. Sentigen Corp. has not yet developed any products or generated any revenue
and has no operating history on which to base an evaluation of its business or
prospects. There is no assurance that Sentigen Corp. will develop any products
and, if such products are developed, that they will be commercially viable,
especially in light of the competition we will face in the industry in which
Sentigen Corp. will compete.


                                       2
<Page>



We may need to raise more money to fund Sentigen Corp.'s research efforts and we
cannot assure you that we will be able to obtain additional financing when
needed.

         We may need to raise more money to fund Sentigen Corp.'s research
efforts and to fully develop commercially viable products. We cannot assure you
that we will be able to obtain additional financing when needed on terms
satisfactory to us, if at all. Our business will be materially adversely
affected if we cannot raise additional capital when needed.


Due to expected fluctuations in our quarterly operating results, you should not
rely on the results of any single quarter as being indicative of our future
results.

         Our quarterly operating results are subject to volatility due to such
factors as the commencement, completion or cancellation of large contracts,
progress of ongoing contracts, acquisitions, the timing of start-up expenses for
new offices and changes in the mix of services. Since a large percentage of our
operating costs are relatively fixed, variations in the timing and progress of
large contracts can materially affect quarterly results. Comparisons of our
quarterly financial results are not necessarily meaningful and should not be
relied upon as an indication of future performance. However, fluctuations in
quarterly results could affect the market price of our common stock in a manner
unrelated to our long term operating performance.


If we are unable to comply with existing government regulations or if existing
government regulations are changed, our business and operations could be
materially and adversely affected.

         The failure on our part to comply with applicable regulations could
result in the termination of ongoing research, sales and marketing or the
disqualification of data for submission to regulatory authorities.

         Furthermore, if we or our customers are notified by any governmental
agency that we have failed to follow or violated accepted practices, our
business and operations could be adversely affected. Our business depends on the
continued strict government regulation of the drug development process,
especially in the United States and Europe. Any relaxation or change in existing
regulations could have a material adverse effect on the demand for the services
we offer. Potential regulatory changes under consideration in the United States
and elsewhere include:

(1)      mandatory substitution of generic drugs for patented drugs;
(2)      relaxation in the scope of regulatory requirements; and
(3)      the introduction of simplified drug approval procedures.

         If future regulatory cost containment efforts limit the profits which
can be derived on new drugs, our customers may reduce their research and
development spending which could reduce the business they outsource to us. These
and other changes in regulation could have a material impact on the business
opportunities available to us, and in turn, reduce the revenues we are able to
generate.

         In addition, the health care industry is subject to changing political,
economic and regulatory influences that may affect the pharmaceutical and
biotechnology industries. During 1994, several comprehensive health care reform
proposals were introduced in Congress. The intent of the proposals were,
generally, to expand health care coverage for the uninsured and reduce the
growth of total health care expenditures. While the proposals were never
adopted, health care reform may again be addressed by Congress. Similar reform
movements have occurred in Europe and Asia. Implementation of government health
care reform may adversely affect research and development expenditures by
pharmaceutical and biotechnology companies which could decrease the business
opportunities available to us. We are unable to predict the likelihood of such
or similar legislation being enacted into law or the effects such legislation
would have on us.

                                       3
<PAGE>


The pharmaceutical and biotechnology industries are subject to strict
environmental regulations.

         Our operations are subject to evolving federal, state and local laws
and regulations relating to the protection of the environment. These laws and
regulations require us to obtain permits. Although we believe that we are in
substantial compliance with all applicable material environmental laws, it is
possible that there are material environmental liabilities of which we are
unaware. If the costs of compliance with the various existing or future
environmental laws and regulations, including any penalties which may be
assessed for failure to obtain the necessary permits, exceed our budgets for
such items, our business could be adversely affected. We may also be required to
expend substantial sums of revenue for damages and cleanup costs due to our
disposal of hazardous waste.


We may be faced with potential liability for injuries resulting from our
products.

         We may be exposed to product liability claims as a result of the sale
of our products. Although we have obtained product liability insurance in the
aggregate amount of $2.0 million ($1.0 million per occurrence), and an umbrella
policy that provides a $10.0 million coverage (per occurrence or aggregate), we
cannot assure you that such insurance will fully cover us against any claims by
our customers. If a successful suit were brought against us, unavailability or
insufficiency of insurance coverage could have a material adverse effect on our
operations. Moreover, any adverse publicity arising from claims made against us,
even if such claims were unsubstantiated and unsuccessful, could adversely
affect our reputation and sales.


The unauthorized use of our proprietary information may have an adverse effect
on our financial condition.

         We utilize various proprietary information in connection with the
provision of our services and the manufacture and sale of our products. We have
also developed processes and formulas with respect to cell and embryo culture
media and reagents and gene expression systems that we believe are proprietary
to us. To protect our proprietary information, we rely on the customary
principles of "work-for-hire" and have entered into non-disclosure agreements
with some of our employees. We cannot assure you, however, that our proprietary
information will be adequately protected. If third parties infringe on our
proprietary information, or independently develop the same type of proprietary
information as ours, our financial condition may be adversely affected.


Defending against claims of intellectual property infringement could be
expensive and could disrupt our business operations.

         We believe that our technology has been independently developed and
does not infringe upon the proprietary rights of others. We cannot assure you,
however, that our technology does not, and will not in the future, infringe upon
the rights of third parties. We may be a party to legal proceedings and claims
relating to the proprietary information of others from time to time in the
ordinary course of our business. We may incur substantial expense in defending
against these third-party infringement claims, regardless of their merit. A
successful claim might subject us to substantial monetary liability and might
require us to modify our products or obtain a license to develop our products.
We may not have sufficient financial or other resources necessary to
successfully defend a patent infringement or other proprietary rights action. We
cannot assure you that we could modify our products or obtain a license to
develop our products if forced to.


If we are unable to retain the services of several key management and technical
employees, our operations may be adversely affected.

         Our success substantially depends on the performance, contributions and
expertise of our senior management team, led by Thomas Livelli, President and
Chief Executive Officer of Cell & Molecular Technologies, Inc. and Kevin J. Lee,
PhD, Executive Vice President for Research of Sentigen. The departure of Mr.
Livelli, Dr. Lee or any key executive could have a material adverse effect on
us. Our performance also depends on our ability to attract and retain qualified
management and professional, scientific and technical operating staff, as well
as our ability to recruit qualified representatives for our contract sales
services. If we are unable to attract and retain qualified personnel, our
business, results of operations or financial condition could be adversely
affected.

                                       4
<page>

The market price of our common stock is highly volatile and there is currently
only a limited trading market in our common stock.

         The market price of our common stock has been highly volatile and may
continue to be volatile in the future. As a result of our stock price
volatility, it is difficult to determine the true market value of our company.
Additionally, in 2001, the average daily trading volume in our common stock was
less than 1,800 shares. The lack of an active trading market could adversely
affect the price of the common stock and your ability to sell shares of our
common stock.


Possible additional issuances will cause dilution.

         While we currently have outstanding 7,451,044 shares of common stock,
options to purchase an aggregate of 1,364,644 shares of common stock and
warrants to purchase an aggregate of 44,810 shares of common stock, we are
authorized to issue up to 20,000,000 shares and are therefore able to issue
additional shares without being required to obtain stockholder approval. Thus,
investors in our common stock could find their holdings drastically diluted,
which if it occurs, means that they will own a smaller percentage.


We currently do not intend to pay cash dividends on our shares.

         We have never declared or paid any cash dividends on our common stock,
nor do we intend on doing so in the future. The payment of dividends, if any, in
the future is within the discretion of our board of directors and will depend
upon our earnings, capital requirements and financial condition as well as other
relevant factors. We currently intend to retain all earnings, if any, to finance
our continued growth and the development of our business. Furthermore, our
ability to declare or pay dividends may be limited in the future by the terms of
any then-existing credit facilities, which may contain covenants that restrict
the payment of cash dividends.


If we do not effectively manage our growth in the future, our operations could
be disrupted or our financial condition could be impaired.

         Growth of our business may place a significant strain on our management
systems and resources and may require us to implement new operating and
financial systems, procedures and controls. The failure to manage our growth and
expansion could adversely affect our business, results of operations and
financial condition.


Our backlog may not be indicative of future results.

         We report backlog based on anticipated net revenue from uncompleted
projects that a customer has authorized. We cannot assure you that the backlog
we have reported will be indicative of our future results. A number of factors
may affect our backlog, including:

(1)      the variable size and duration of projects (some are performed over
         several years);
(2)      the loss or delay of projects; and
(3)      a change in the scope of work during the course of a project.

                                       5
<page>

Our charter documents and Delaware law may inhibit a takeover of our company.

         Provisions in our certificate of incorporation and bylaws may have the
effect of delaying or preventing a change of control or changes in our
management that a stockholder might consider favorable. These provisions
include, among others:

(1)      the right of the board to elect a director to fill a space created by
         the expansion of the board;
(2)      the ability of the board to alter our bylaws; and
(3)      the ability of the board to issue series of preferred stock without
         stockholder approval.






                                       6